DSW stock plunges after full-year adjusted profit misses expectations

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 6 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 6%
  • Publisher: 97%

Business Business Headlines News

Business Business Latest News,Business Business Headlines

Shoe retailer DSW's stock plunges after full-year adjusted profit misses

Shares of DSW Inc. DSW, -0.16% plunged 8.7% in premarket trade Tuesday, after the discount footwear retailer reported full-year earnings that missed expectations, while fiscal fourth-quarter revenue beat. The company swung to a net loss for the quarter to Feb. 2 of $45.7 million, or 58 cents a share, from a profit of $12.0 million, or 15 cents a share, in the year-ago period.

Have breaking news sent to your inbox. Subscribe to MarketWatch's free Bulletin emails. Sign up here.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 3. in BUSİNESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

BioScrip's stock soars after merger deal with Option Care, owned by Walgreens and Madison DearbornShares of BioScrip Inc. soared 32% toward a 4-year high in premarket trade Friday, after the company announced a deal to merge with privately held Option Care Enterprises Inc., a provider of home and alternate treatment site infusion therapy services owned by funds affiliated with Walgreens Boots Alliance Inc. and private-equity firm Madison Dearborn Partners LLC (MDP). BioScrip's stock is halted for news until 7:30 a.m. Eastern. Under terms of the agreement, BioScrip will issue new shares to Option Care's shareholder and Walgreens and MDP will own about 80% of the combined publicly traded company. BioScrip's market capitalization was about $446.9 million as of Thursday's close. "This is a compelling and complementary fit of two leading players in the U.S. infusion market," said BioScrip Chief Executive Daniel Greenleaf. "Together, we will be able to provide a diverse set of life-improving and cost-effective services to more patients across the United States." BioScrip's stock has rallied 31% over the past 12 months, while the SPDR Health Care Select Sector ETF has gained 6.9% and the Dow Jones Industrial Average has tacked on 3.4%.
Source: MarketWatch - 🏆 3. / 97 Read more »

'Disappointing' timing on Model Y crossover pushes Tesla's stock downShares of Tesla Inc. dropped after what analysts described as an underwhelming reveal of the company's latest electric vehicle, the Model Y crossover. screw what wall st analysts think. telsa is selling cars. wall st just hates Elon musk cuz he calls them on their bullshit Designed by Tesla chief designer, Stevie Wonder. Tesla, the DeLorean of the 21st century.
Source: latimes - 🏆 11. / 82 Read more »

Boeing shares dip again as more countries ground 737 MAX 8 planesBoeing Co's fall in stock market value this week soared past $20 billion on... Anything US made in China will DESTROY US reputation. Get OUT OF CHINA NOW At least $CRON flying Too Good..Sue these Boeing BoeingAirplanes EthiopianAirlinesCrash LionAir
Source: Reuters - 🏆 2. / 97 Read more »